CAR T-cell therapy versus allogeneic HSCT for relapsed or refractory mantle cell lymphoma.

Gloria Iacoboni, Sascha Dietrich, Nora Liebers

Journal: The Lancet. Haematology 2023;10(12):e951-e952

PMID: 38030316

Full Text on Elsevier Science View on PubMed

Abstract

Address: Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. Electronic address: [email protected].; Department of Hematology, University Hospital of Düsseldorf and Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf, Düsseldorf, Germany. Electronic address: [email protected].; Department of Hematology, University Hospital of Düsseldorf and Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf, Düsseldorf, Germany.

DOI: 10.1016/S2352-3026(23)00335-6

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Humans, Hematopoietic Stem Cell Transplantation, Immunotherapy, Adoptive, Lymphoma, Mantle-Cell, Neoplasm Recurrence, Local, Transplantation, Homologous